Vitamin D receptor gene polymorphisms are associated with psoriasis susceptibility and the clinical response to calcipotriol in psoriatic patients

Abstract

Psoriasis is a common genetic disease characterized by hyperproliferation and disordered maturation of keratinocytes. To date, many association studies between psoriasis and VDR gene have been conducted, but the results are controversial. Furthermore, vitamin D 3 analogue has anti-psoriatic activity; however, the clinical response is variable. This study was conducted to explore whether VDR gene polymorphisms are associated with psoriasis susceptibility and clinical response to calcipotriol in psoriatic patients. A total of 110 patients and 183 controls were genotyped for VDR gene polymorphisms rs2228570, rs731236, rs1544410 and rs7975232 by LDR method. SNP-based and haplotype-based association analyses were subsequently performed. Patients with PASI < 3 were treated with calcipotriol ointment monotherapy. After 6 weeks of therapy, the correlations between efficacy and the genotypes of each polymorphism were evaluated. The results showed that for rs7975232, allele A was significantly over-represented in psoriasis patients relative to controls (39.09% vs. 27.05%, OR (95% CI) = 1.731 (1.213-2.471)), and compared with the reference CC genotype, the following ORs were observed: AA genotype OR = 2.404 (95% CI: 1.085-5.328; P = .034) and GA genotype OR = 2.143 (95% CI: 1.283-3.579; P = .005). Haplotype analyses showed that the rs2228570/rs731236/rs1544410/ rs7975232 CTGA was significantly over-represented in psoriasis patients compared with controls (OR (95% CI)=1.907 (1.132-3.214); P = .020). Among the patients with PASI < 3, the response rates to calcipotriol were significantly higher in patients with rs7975232 CC genotypes than in those with other genotypes (x 2 = 9.172, P = .010). These data suggest that VDR polymorphisms are associated with psoriasis susceptibility and clinical response to calcipotriol in psoriatic patients.

Disturbed expression of vitamin D and retinoic acid‐related orphan receptors α and γ and of megalin in inflammatory skin diseases

“…26,45 The therapeutic action of the active forms of vitamin D is mediated by its receptor, VDR. Additionally, the VDR polymorphism is linked to psoriasis susceptibility 27,28 and susceptibility of psoriatic patients to the vitamin D-based treatment. The reduced VDR levels in psoriatic skin are related to the reduced tight junctions.…”

Recent progress at the psoriasis and atopic dermatitis research front: An experimental dermatology perspective

“…Vitamin D3 analogues have long been used as anti‐psoriatic agents, but the elicited clinical response is quite variable. Genotyping analysis for VDR gene polymorphisms found that VDR gene polymorphisms are closely associated with PSO susceptibility and clinical response to calcipotriol in PSO patients 84 . This study suggests that VDR gene sequencing may be performed to predict PSO treatment response to calcipotriol.…”

Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics

“…Interestingly, several studies identified an association between polymorphisms of vitamin D receptor (VDR) and psoriasis susceptibility [ 43 ]. However, this is still controversial [ 53 , 54 ]. The mechanism of vitamin D is mediated by the vitamin D receptor (VDR), and after its activation, it interacts with retinoid X receptor (RXR) to form a heterodimeric complex.…”